A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA
mPV inadequately managed by at least one standard immunosuppressive therapies
Active mPV at screening
Anti-DSG3 antibody ELISA positive at screening
Active cutaneous lesions associated with PV that indicates mucocutaneous rather than mucosal-dominant disease
Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3 antibody titers have recently increased
Prednisone > 0.25mg/kg/day
Other autoimmune disorder requiring immunosuppressive therapies
Cabaletta Bio
Lead sponsor